Nxera Pharma Co., Ltd. (SOLTF)

8,92 -0,80 (-8,27%) Börsenschluss: 03:45PM EDT

Nxera Pharma Co., Ltd.

PMO Hanzomon
11th Floor 2-1 Kojimachi Chiyoda-ku
Tokyo 102-0083
Japan
81 3 5210 3290
https://www.nxera.life

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 350

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Shinichi Tamura	Founder & Chairman of the Board	1,49M	N/A	1949
Mr. Christopher Cargill	Representative Executive Officer, President, CEO & Director	1,27M	N/A	1984
Mr. Hironoshin Nomura	Executive Officer, Executive VP & CFO	N/A	N/A	1983
Mr. Toshihiro Maeda	Executive VP & COO	N/A	N/A	N/A
Mr. Kieran Johnson F.C.A.	Executive Officer, Executive VP & Chief Accounting Officer	N/A	N/A	1969
Mr. Kazuhiko Yoshizumi	Executive Officer, Executive VP & Chief Compliance Officer	N/A	N/A	1954
Shinichiro Nishishita	VP of Investor Relations & Head of Regulatory Disclosures	N/A	N/A	N/A
Stacey Southall	Associate Director & Head of Biophysics	N/A	N/A	N/A
Ms. Candelle Chong	Executive Officer, Executive VP & Chief of Staff	N/A	N/A	1989
Dr. Satoshi Tanaka	Executive Officer, Executive VP & President of Idorsia Pharmaceuticals Japan	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company's development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.

Corporate Governance

Nxera Pharma Co., Ltd.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.